IL2 and renal cell carcinoma: Also, despite that a previous study in renal cell carcinoma patients suggested that monotherapy with IL-2 does not affect the frequency of cells with a MDSC phenotype [28], we cannot rule out that the IL-2 component may have contributed to the observed reduction of MDSCs.